Vici P - Search Results

1

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G. Generali D, et al. Among authors: vici p. Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21. Oncologist. 2017. PMID: 28432226 Free PMC article. Clinical Trial.

2

Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer.

Lopez M, Vici P, Carpano S, Natali M, Ganzina F, Conti EM, Di Lauro L. Lopez M, et al. Among authors: vici p. J Cancer Res Clin Oncol. 1991;117(1):61-4. doi: 10.1007/BF01613198. J Cancer Res Clin Oncol. 1991. PMID: 1997473 Clinical Trial.

3

5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.

Lopez M, Papaldo P, Di Lauro L, Vici P, Carpano S, Conti EM. Lopez M, et al. Among authors: vici p. Oncology. 1989;46(1):1-5. doi: 10.1159/000226671. Oncology. 1989. PMID: 2915887 Clinical Trial.

4

Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.

Lopez M, Vici P, Di Lauro L, Paoletti G, Gionfra T, Conti F, Carpano S, Pignatti F, Giannarelli D. Lopez M, et al. Among authors: vici p. Eur J Cancer. 1995 Sep;31A(10):1611-4. doi: 10.1016/0959-8049(95)00200-3. Eur J Cancer. 1995. PMID: 7488410 Clinical Trial.

5

Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.

Botti C, Vici P, Lopez M, Scinto AF, Cognetti F, Cavaliere R. Botti C, et al. Among authors: vici p. J Am Coll Surg. 1995 Sep;181(3):202-8. J Am Coll Surg. 1995. PMID: 7670678

6

Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer.

Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S. Lopez M, et al. Among authors: vici p. Cancer. 1993 Jul 15;72(2):502-5. doi: 10.1002/1097-0142(19930715)72:2<502::aid-cncr2820720228>3.0.co;2-1. Cancer. 1993. PMID: 8319180

7

Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer.

Vici P, Di Lauro L, Carpano S, Amodio A, Pignatti F, Casali A, Conti F, Lopez M. Vici P, et al. Oncology. 1996 Jan-Feb;53(1):16-8. doi: 10.1159/000227528. Oncology. 1996. PMID: 8570125 Clinical Trial.

8

[Simultaneous infusion of vinorelbin and taxol as first-line chemotherapy in metastasized breast cancer].

Vici P, Conti F, Amodio A, Belli F, Della Giulia M, Mariotti S, Gionfra T, Lopez M. Vici P, et al. Clin Ter. 1998 Jul-Aug;149(4):255-9. Clin Ter. 1998. PMID: 9866885 Italian.

9

First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer.

Vici P, Amodio A, Di Lauro L, Conti F, Gionfra T, Belli F, Lopez M. Vici P, et al. Oncology. 2000;58(1):3-7. doi: 10.1159/000012071. Oncology. 2000. PMID: 10644933 Clinical Trial.

10

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

Mottolese M, Benevolo M, Del Monte G, Buglioni S, Papaldo P, Nisticò C, Di Filippo F, Vasselli S, Vici P, Botti C. Mottolese M, et al. Among authors: vici p. J Cancer Res Clin Oncol. 2000 Dec;126(12):722-9. doi: 10.1007/pl00008478. J Cancer Res Clin Oncol. 2000. PMID: 11153146

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters